15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Immunitybio Inc, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $12.00 to $23.00, a moderate spread. The average target of $16.67 sits 139% above the current $6.96. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.07 next quarter toward $0.06 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Immunitybio Inc.
As of Jul, 5 of 5 firms rate IBRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IBRX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.07
Range $-0.07 – $-0.07 · 1 analysts · +0% YoY
Next period, 1 analysts expect Immunitybio Inc to earn $-0.07 a share (range $-0.07 – $-0.07), versus $-0.07 a year earlier. Full-year consensus is $-0.85, growing to $0.06 the year after.
REVENUE · NEXT QUARTER
$57.7M
Range $50.3M – $66.0M · 1 analysts · +80% YoY
Revenue is expected to reach $57.7M (range $50.3M – $66.0M), +79.8% year-over-year. Full-year consensus is $222.4M, rising to $452.0M next year.
Top analysts covering Immunitybio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IBRX.
#1
Andres Y. Maldonado
HC Wainwright & Co. · Rank #211
Buy
$15.00+115.4% to target
Overall win rate
38%
+ Follow
#2
Jason Kolbert
D. Boral Capital · Rank #346
Buy
$23.00+230.2% to target
Overall win rate
22%
+ Follow
#3
JM
Jeet Mukherjee
BTIG
Buy
$12.00+72.3% to target
Coverage
—
+ Follow
#4
CD
Clara Dong
Jefferies
Buy
$9.00+29.2% to target
Coverage
—
+ Follow
IBRX stock forecast FAQ
What is IBRX's average 12-month price target?+
The 3 analysts with a live target average $16.67 for Immunitybio Inc over the next 12 months, ranging from a $23.00 high to a $12.00 low.
Is IBRX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IBRX?+
The Street-high target is $23.00 (D. Boral Capital), and the Street-low is $12.00 (BTIG). The average of all 3 active targets is $16.67.
How many Wall Street analysts cover IBRX?+
5 analysts have an active rating on Immunitybio Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering IBRX?+
Among analysts who currently cover IBRX, Andres Y. Maldonado of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #211). Their current call is Buy with a $15.00 target.
What is Immunitybio Inc's projected EPS for next quarter?+
The consensus estimate is $-0.07 per share (range $-0.07 – $-0.07) across 1 analysts. Full-year EPS is projected at $-0.85, rising to $0.06 the following year.
How much revenue is Immunitybio Inc expected to report next quarter?+
Consensus revenue is $57.7M (range $50.3M – $66.0M). Full-year revenue is projected at $222.4M, growing to $452.0M next year.
Have analysts been upgrading or downgrading IBRX lately?+
As of Jul, 5 of 5 firms rate IBRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IBRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
